Citizens Jmp Increases DBV Technologies (NASDAQ:DBVT) Price Target to $47.00

DBV Technologies (NASDAQ:DBVT) had its target price raised by analysts at Citizens Jmp from $45.00 to $47.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 126.56% from the stock’s current price.

A number of other research analysts also recently weighed in on DBVT. Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research report on Thursday, December 18th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, DBV Technologies has a consensus rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $20.75 on Friday. DBV Technologies has a one year low of $5.30 and a one year high of $26.18. The company has a market cap of $1.15 billion, a PE ratio of -4.01 and a beta of -0.97. The firm’s 50 day simple moving average is $21.60 and its 200 day simple moving average is $17.15.

Institutional Trading of DBV Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Allworth Financial LP bought a new position in shares of DBV Technologies in the 4th quarter worth $32,000. Royal Bank of Canada purchased a new stake in shares of DBV Technologies during the 4th quarter valued at $34,000. New York State Common Retirement Fund bought a new stake in shares of DBV Technologies during the 3rd quarter worth $34,000. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% in the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares in the last quarter. Finally, Truvestments Capital LLC grew its position in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after acquiring an additional 1,620 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.